The VALIANT trial (NCT06196879) is a Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group clinical trial that evaluated the safety and efficacy of verekitug for ...
The landscape of peptide-based research continues to broaden as investigators pursue compounds capable of interacting with molecular networks involved in cellular communication, structural maintenance ...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the ...
"Leptin resistance is a major barrier to treating obesity," senior author Işın Çakır said in a Pitt news release via UPMC.
A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, ...
Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that the ...
The field of plant stress biology has become increasingly crucial as climate change drives heightened frequencies and severities of abiotic stresses such as ...
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadershipWill build ...
Growth factors can actually increase collagen production and repair skin.
When running a fever during infection, we often feel chills, which prompt us to take action to warm ourselves, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results